A similar strategy by Wanatabe et al. employed oncolytic adenovirus armed with TNFα and IL2 to enhance both human and mouse mesothelin specific CAR T. Treatment with Ad5/3-OAd-TNFα-IL2 induced more robust and persistent localization of human CAR T in the tumour and correspondingly induced sustained regression. Here, TNF is linked to neoplasm.